Literature DB >> 34052525

Muscle multiorgan crosstalk with MG53 as a myokine for tissue repair and regeneration.

Bryan A Whitson1, Tao Tan1, Nianqiao Gong2, Hua Zhu1, Jianjie Ma3.   

Abstract

Through stress and injury to tissues, the cell membrane is damaged and can lead to cell death and a cascade of inflammatory events. Soluble factors that mitigate and repair membrane injury are important to normal homeostasis and are a potential therapeutic intervention for regenerative medicine. A myokine is a type of naturally occurring factors that come from muscle and have impact on remote organs. MG53, a tripartite motif-containing family protein, is such a myokine which has protective effects on lungs, kidneys, liver, heart, eye, and brain. Three mechanisms of action for the beneficial regenerative medicine potential of MG53 have been identified and consist of 1) repair of acute injury to the cellular membrane, 2) anti-inflammatory effects associated with chronic injuries, and 3) rejuvenation of stem cells for tissue regeneration. As such, MG53 has the potential to be a novel and effective regeneration medicine therapeutic.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell membrane repair; MG53; Myokine; Regenerative medicine; TRIM protein

Year:  2021        PMID: 34052525     DOI: 10.1016/j.coph.2021.04.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  3 in total

1.  Resealing and rebuilding injured muscle.

Authors:  Elizabeth M McNally; Alexis R Demonbreun
Journal:  Science       Date:  2021-10-14       Impact factor: 63.714

2.  MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer.

Authors:  Haichang Li; Pei-Hui Lin; Pranav Gupta; Xiangguang Li; Serena Li Zhao; Xinyu Zhou; Zhongguang Li; Shengcai Wei; Li Xu; Renzhi Han; Jing Lu; Tao Tan; Dong-Hua Yang; Zhe-Sheng Chen; Timothy M Pawlik; Robert E Merritt; Jianjie Ma
Journal:  Mol Cancer       Date:  2021-09-14       Impact factor: 27.401

3.  TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA.

Authors:  Zheng Wang; Haixia Li; Hongxia Wang; Xin Li; Qiong Zhang; Haifang Wang; Kui Li; Yurong Qiu
Journal:  Anticancer Drugs       Date:  2022-06-01       Impact factor: 2.248

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.